{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:34:59Z","timestamp":1789749299370,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clusterin is a multifunctional protein, which is associated with the pathogenesis and the development of Alzheimer\u2019s disease (AD). Compared with normal controls, inconsistent results have yielded in previous studies for concentration of cerebrospinal fluid (CSF) clusterin in AD patients. We explored CSF clusterin levels in different pathological processes of AD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Following the National Institute on Aging-Alzheimer\u2019s Association (NIA-AA) criteria, we employed on the levels of CSF A\u03b2<jats:sub>42<\/jats:sub>(A), phosphorylated-Tau (T), and total-tau (N). Based on previously published cutoffs and the close correlation between CSF p-tau and t-tau, 276 participants from the publicly available ADNI database with CSF biomarkers were divided into four groups: A-(TN)- (normal A\u03b2<jats:sub>42<\/jats:sub> and normal p-tau and t-tau; <jats:italic>n<\/jats:italic>\u00a0=\u200950), A+(TN)- (abnormal A\u03b2<jats:sub>42<\/jats:sub> and normal p-tau and t-tau; <jats:italic>n<\/jats:italic>\u00a0=\u200939), A+(TN)\u2009+\u2009(abnormal A\u03b2<jats:sub>42<\/jats:sub> and abnormal p-tau or t-tau; <jats:italic>n<\/jats:italic>\u00a0=\u2009147), A-(TN)\u2009+\u2009(normal A\u03b2<jats:sub>42<\/jats:sub> and abnormal p-tau or t-tau; <jats:italic>n<\/jats:italic>\u00a0=\u200940). To assess CSF clusterin levels in AD continuum, intergroup differences in four groups were compared. Pairwise comparisons were conducted as appropriate followed by Bonferroni post hoc analyses. To further study the relationships between CSF clusterin levels and AD core pathological biomarkers, we employed multiple linear regression method in subgroups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the A-(TN)- group, CSF clusterin levels were decreased in A+ (TN)- group (<jats:italic>P<\/jats:italic>\u00a0=\u20090.002 after Bonferroni correction), but increased in the A+(TN)\u2009+\u2009group and the A-(TN)\u2009+\u2009group (both <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001 after Bonferroni correction). Moreover, we found CSF clusterin levels are positively associated with CSF A\u03b2<jats:sub>42<\/jats:sub> (\u03b2\u2009=\u20090.040, <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00. 001), CSF p-tau (\u03b2\u2009=\u20090.325, <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001) and CSF t-tau (\u03b2\u2009=\u20090.346, <jats:italic>P<\/jats:italic>\u00a0&lt;\u2009\u00a00.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our results indicated that there are differences levels of CSF clusterin in different stages of AD pathology. The CSF clusterin level decreased at the early stage are related to abnormal A\u03b2 pathology; and the increased levels are associated with tau pathology and neurodegeneration.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-022-03038-w","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T04:29:22Z","timestamp":1672374562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Dynamic changes of CSF clusterin levels across the Alzheimer\u2019s disease continuum"],"prefix":"10.1186","volume":"22","author":[{"given":"Lian","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Bo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling-Zhi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Peng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Shan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"issue":"9770","key":"3038_CR1","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S0140-6736(10)61349-9","volume":"377","author":"C Ballard","year":"2011","unstructured":"Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer\u2019s disease. The Lancet. 2011;377(9770):1019\u201331.","journal-title":"The Lancet"},{"issue":"3","key":"3038_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease:implications for prevention trials. Neuron. 2014;84(3):608\u201322.","journal-title":"Neuron"},{"issue":"2","key":"3038_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207\u201316.","journal-title":"Lancet Neurol"},{"key":"3038_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3389\/fnins.2019.00164","volume":"13","author":"EM Foster","year":"2019","unstructured":"Foster EM, Dangla-Valls A, Lovestone S, Ribe EM, Buckley NJ. Clusterin in Alzheimer\u2019s Disease: Mechanisms, Genetics, and Lessons From Other Pathologies. Front Neurosci. 2019;13:164.","journal-title":"Front Neurosci"},{"issue":"2","key":"3038_CR5","first-page":"191","volume":"1","author":"SL Rosenthal","year":"2012","unstructured":"Rosenthal SL, Wang X, Demirci FY, Barmada MM, Ganguli M, Lopez OL, et al. Beta-Amyloid Toxicity Modifier Genes and the Risk of Alzheimer\u2019s Disease. Am J Neurodegener Dis. 2012;1(2):191\u20138.","journal-title":"Am J Neurodegener Dis"},{"issue":"10","key":"3038_CR6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/ng.440","volume":"41","author":"D Harold","year":"2009","unstructured":"Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1088\u201393.","journal-title":"Nat Genet"},{"issue":"10","key":"3038_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/ng.439","volume":"41","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer\u2019s disease. Nat Genet. 2009;41(10):1094\u20139.","journal-title":"Nat Genet"},{"issue":"8","key":"3038_CR8","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.neuint.2005.12.005","volume":"48","author":"AM Nilselid","year":"2006","unstructured":"Nilselid AM, Davidsson P, Nagga K, Andreasen N, Fredman P, Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem Int. 2006;48(8):718\u201328.","journal-title":"Neurochem Int"},{"issue":"7","key":"3038_CR9","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1007\/s11064-008-9588-x","volume":"33","author":"C Sihlbom","year":"2008","unstructured":"Sihlbom C, Davidsson P, Sjogren M, Wahlund LO, Nilsson CL. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer\u2019s disease patients and healthy individuals. Neurochem Res. 2008;33(7):1332\u201340.","journal-title":"Neurochem Res"},{"issue":"208","key":"3038_CR10","first-page":"e1","volume":"37","author":"Y Deming","year":"2016","unstructured":"Deming Y, Xia J, Cai Y, Lord J, Holmans P, Bertelsen S, et al. A potential endophenotype for Alzheimer\u2019s disease: cerebrospinal fluid clusterin. Neurobiol Aging. 2016;37(208):e1\u20139.","journal-title":"Neurobiol Aging"},{"issue":"1\u20132","key":"3038_CR11","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.molbrainres.2003.08.005","volume":"118","author":"M Puchades","year":"2003","unstructured":"Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer\u2019s disease. Brain Res Mol Brain Res. 2003;118(1\u20132):140\u20136.","journal-title":"Brain Res Mol Brain Res"},{"issue":"5","key":"3038_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3233\/JAD-2001-3501","volume":"3","author":"AM Lidstr\u00f6m","year":"2001","unstructured":"Lidstr\u00f6m AM, Hessea C, Rosengrena L, Fredmana P, Davidssona P, Blennow K. Normal levels of clusterin in cerebrospinal fluid in Alzheimer\u2019s disease, and no change after acute ischemic stroke. J Alzheimers Dis. 2001;3(5):435\u201342.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"3038_CR13","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2174\/1567205016666191024141757","volume":"16","author":"X Shi","year":"2019","unstructured":"Shi X, Xie B, Xing Y, Tang Y. Plasma Clusterin as a Potential Biomarker for Alzheimer\u2019s Disease-A Systematic Review and Meta-analysis. Curr Alzheimer Res. 2019;16(11):1018\u201327.","journal-title":"Curr Alzheimer Res"},{"issue":"1","key":"3038_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s11011-018-0325-0","volume":"34","author":"C Yang","year":"2019","unstructured":"Yang C, Wang H, Li C, Niu H, Luo S, Guo X. Association between clusterin concentration and dementia: a systematic review and meta-analysis. Metab Brain Dis. 2019;34(1):129\u201340.","journal-title":"Metab Brain Dis"},{"issue":"5","key":"3038_CR15","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/sj.jcbfm.9600419","volume":"27","author":"RD Bell","year":"2007","unstructured":"Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer\u2019s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27(5):909\u201318.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"13","key":"3038_CR16","first-page":"7563","volume":"270","author":"E Matsubara","year":"1995","unstructured":"Matsubara E, Frangione B, Ghiso J. Characterization of Apolipoprotein J-Alzheimer\u2019s A\u03b2. Interaction. 1995;270(13):7563\u20137.","journal-title":"Interaction."},{"issue":"1","key":"3038_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1006\/exnr.1995.1080","volume":"136","author":"T Oda","year":"1995","unstructured":"Oda T, Wals P, Osterburg HH, Johnson SA, Pasinetti GM, Morgan TE, et al. Clusterin (apoJ) alters the aggregation of amyloid beta-peptide (A beta 1\u201342) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp Neurol. 1995;136(1):22\u201331.","journal-title":"Exp Neurol"},{"issue":"2","key":"3038_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0896-6273(03)00850-X","volume":"41","author":"RB DeMattos","year":"2004","unstructured":"DeMattos RB, Cirrito JR, Parsadanian M, May PC, O\u2019Dell MA, Taylor JW, et al. ApoE and Clusterin Cooperatively Suppress Abeta Levels and Deposition: Evidence that ApoE Regulates Extracellular Abeta Metabolism In Vivo. Neuron. 2004;41(2):193\u2013202.","journal-title":"Neuron"},{"issue":"1","key":"3038_CR19","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1038\/s41467-021-25060-1","volume":"12","author":"P Yuste-Checa","year":"2021","unstructured":"Yuste-Checa P, Trinkaus VA, Riera-Tur I, Imamoglu R, Schaller TF, Wang H, et al. The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model. Nat Commun. 2021;12(1):4863.","journal-title":"Nat Commun"},{"issue":"5","key":"3038_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","volume":"87","author":"CRJ Jack","year":"2016","unstructured":"Jack CRJ, Bennett DA, Blennow K, Carrillo MC, Feldman HH, Frisoni GB, et al. A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539\u201347.","journal-title":"Neurology"},{"issue":"4","key":"3038_CR21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3038_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC, Aisen PS, Beckett LA, Donohue MC, Gamst AC, Harvey DJ, et al. Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010;74(3):201\u20139.","journal-title":"Neurology"},{"issue":"3","key":"3038_CR23","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jalz.2010.03.008","volume":"6","author":"JQ Trojanowski","year":"2010","unstructured":"Trojanowski JQ, Vandeerstichele H, Korecka M, Clark CM, Aisen PS, Petersen RC, et al. Update on the biomarker core of the Alzheimer\u2019s Disease Neuroimaging Initiative subjects. Alzheimers Dement. 2010;6(3):230\u20138.","journal-title":"Alzheimers Dement"},{"key":"3038_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.clinbiochem.2019.05.006","volume":"72","author":"LM Shaw","year":"2019","unstructured":"Shaw LM, Hansson O, Manuilova E, Masters CL, Doecke JD, Li QX, et al. Method comparison study of the Elecsys(R) beta-Amyloid (1\u201342) CSF assay versus comparator assays and LC-MS\/MS. Clin Biochem. 2019;72:7\u201314.","journal-title":"Clin Biochem"},{"issue":"2","key":"3038_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nmeth.2763","volume":"11","author":"JJ Kennedy","year":"2014","unstructured":"Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, et al. Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods. 2014;11(2):149\u201355.","journal-title":"Nat Methods"},{"issue":"1","key":"3038_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jalz.2018.06.3058","volume":"15","author":"Y Tang","year":"2019","unstructured":"Tang Y, Lutz MW, Xing Y. A systems-based model of Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(1):168\u201371.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3038_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, Therneau TM, Lowe VJ, Knopman DS, et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 2017;13(3):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"3038_CR28","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimers Dement"},{"issue":"Pt 1","key":"3038_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1042\/bj2930027","volume":"293","author":"J Ghiso","year":"1993","unstructured":"Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T, et al. The cerebrospinal-fluid soluble form of Alzheimer\u2019s amyloid beta is complexed to SP-40,40(apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J. 1993;293(Pt 1):27\u201330.","journal-title":"Biochem J"},{"key":"3038_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.nbd.2017.04.003","volume":"103","author":"Y Wang","year":"2017","unstructured":"Wang Y, Qin X, Paudel HK. Amyloid beta peptide promotes lysosomal degradation of clusterin via sortilin in hippocampal primary neurons. Neurobiol Dis. 2017;103:78\u201388.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"3038_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/0896-6273(90)90342-D","volume":"5","author":"P May","year":"1990","unstructured":"May P, Lampert-Etchells M, Johnson S, Poirier J, Masters J, Finch C. Dynamics of gene expression for a hip- pocampal glycoprotein elevated in Alzheimer\u2019s disease and in response to experimental lesions in rat. Neuron. 1990;5(6):831\u20139.","journal-title":"Neuron"},{"issue":"2","key":"3038_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1006\/exnr.1998.6892","volume":"154","author":"AM Lidstr\u00f6m","year":"1998","unstructured":"Lidstr\u00f6m AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, Blennow K. Clusterin (Apolipoprotein J) Protein Levels Are Increased in Hippocampus and in Frontal Cortex in Alzheimer\u2019s Disease. Exp Neurol. 1998;154(2):511\u201321.","journal-title":"Exp Neurol"},{"issue":"1","key":"3038_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13024-021-00426-7","volume":"16","author":"F Chen","year":"2021","unstructured":"Chen F, Swartzlander DB, Ghosh A, Fryer JD, Wang B, Zheng H. Clusterin secreted from astrocyte promotes excitatory synaptic transmission and ameliorates Alzheimer\u2019s disease neuropathology. Mol Neurodegener. 2021;16(1):5.","journal-title":"Mol Neurodegener"},{"issue":"3","key":"3038_CR34","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/bpa.12392","volume":"27","author":"JS Miners","year":"2017","unstructured":"Miners JS, Clarke P, Love S. Clusterin levels are increased in Alzheimer\u2019s disease and influence the regional distribution of Abeta. Brain Pathol. 2017;27(3):305\u201313.","journal-title":"Brain Pathol"},{"issue":"1","key":"3038_CR35","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s40478-020-01079-1","volume":"8","author":"AM Wojtas","year":"2020","unstructured":"Wojtas AM, Carlomagno Y, Sens JP, Kang SS, Jensen TD, Kurti A, et al. Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation. Acta Neuropathol Commun. 2020;8(1):210.","journal-title":"Acta Neuropathol Commun"},{"issue":"Suppl 1","key":"3038_CR36","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.neurobiolaging.2011.09.003","volume":"32","author":"DM Holtzman","year":"2011","unstructured":"Holtzman DM. CSF biomarkers for Alzheimer\u2019s disease: current utility and potential future use. Neurobiol Aging. 2011;32(Suppl 1):S4\u20139.","journal-title":"Neurobiol Aging"},{"issue":"4","key":"3038_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s004010050815","volume":"95","author":"P Giannakopoulos","year":"1998","unstructured":"Giannakopoulos P, K\u00f6vari E, French LE, Viard I, Hof PR, Bouras C. Possible neuroprotective role of clusterin in Alzheimer\u2019s disease: a quantitative immunocytochemical study. Acta Neuropathol. 1998;95(4):387\u201394.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"3038_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/cdd.2010.169","volume":"18","author":"O Cordero-Llana","year":"2011","unstructured":"Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, et al. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death Differ. 2011;18(5):907\u201313.","journal-title":"Cell Death Differ"},{"issue":"2","key":"3038_CR39","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.nbd.2005.11.009","volume":"22","author":"A Imhof","year":"2006","unstructured":"Imhof A, Charnay Y, Vallet PG, Aronow B, Kovari E, French LE, et al. Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiol Dis. 2006;22(2):274\u201383.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"3038_CR40","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.neuron.2013.12.003","volume":"80","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Holtzman DM. Biomarker modeling of Alzheimer\u2019s disease. Neuron. 2013;80(6):1347\u201358.","journal-title":"Neuron"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-022-03038-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-022-03038-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T04:29:51Z","timestamp":1672374591000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-022-03038-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["3038"],"URL":"https:\/\/doi.org\/10.1186\/s12883-022-03038-w","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"27 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our data were obtained from ADNI website, which data were shared. Its data-sharing policy making us available to all data. In accordance with the Declaration of Helsinki, written informed consent was acquired from all the participants or their representatives. ADNI was approved by the institutional review boards of all the participating institutions. For latest information, see ADNI website.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}